Maxim Group Believes Bluebird Bio (NASDAQ: BLUE) Won’t Stop Here

By Jason Carr

In a report released today, Jason McCarthy from Maxim Group reiterated a Buy rating on Bluebird Bio (NASDAQ: BLUE), with a price target of $100. The company’s shares opened today at $90, close to its 52-week high of $100.40.

McCarthy observed:

“bluebird announced updated data at the ongoing ASCO (American Society of Clinical Oncology) meeting for bb2121 CAR-T in the CRB-401 Phase 1 study targeting relapsed/refractory multiple myeloma (r/r/ MM).”

According to, McCarthy is ranked 0 out of 5 stars with an average return of -11.7% and a 35.2% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as ImmunoCellular Therapeutics, Mateon Therapeutics Inc, and Soleno Therapeutics Inc.

Currently, the analyst consensus on Bluebird Bio is Strong Buy and the average price target is $91, representing a 1.1% upside.

In a report issued on May 30, Standpoint Research also initiated coverage with a Buy rating on the stock.

The company has a one year high of $100.40 and a one year low of $36.62. Currently, Bluebird Bio has an average volume of 660K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

bluebird bio, Inc. is a clinical-stage biotechnology company. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.